toripalimab
coherus,junshi biosciences
['toripalimab']
addition of toripalimab to 1l chemotherapy for non-squamous had an even greater impact with an os hr 0.49, mos 27.8m vs 15.9m, 3y os rate 41% vs 18.9%. odd though that os hr 0.91 in pdl1 high subgroup. related to high crossover rate? #asco23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo